Inter-fraction robustness of intensity-modulated proton therapy in the post-operative treatment of oropharyngeal and oral cavity squamous cell carcinomas.
Aged
Carcinoma, Squamous Cell
/ diagnostic imaging
Dose Fractionation, Radiation
Female
Humans
Male
Middle Aged
Mouth Neoplasms
/ diagnostic imaging
Organs at Risk
/ radiation effects
Oropharyngeal Neoplasms
/ diagnostic imaging
Pilot Projects
Postoperative Care
Proton Therapy
/ methods
Radiotherapy Planning, Computer-Assisted
Radiotherapy, Intensity-Modulated
/ methods
Retrospective Studies
Spinal Cord
/ radiation effects
Uncertainty
Journal
The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
pubmed:
18
12
2019
medline:
28
2
2020
entrez:
18
12
2019
Statut:
ppublish
Résumé
To evaluate dosimetric consequences of inter-fraction setup variation and anatomical changes in patients receiving multifield optimised (MFO) intensity modulated proton therapy for post-operative oropharyngeal (OPC) and oral cavity (OCC) cancers. Six patients receiving MFO for post-operative OPC and OCC were evaluated. Plans were robustly optimised to clinical target volumes (CTVs) using 3 mm setup and 3.5% range uncertainty. Weekly online cone beam CT (CBCT) were performed. Planning CT was deformed to the CBCT to create virtual CTs (vCTs) on which the planned dose was recalculated. vCT plan robustness was evaluated using a setup uncertainty of 1.5 mm and range uncertainty of 3.5%. Target coverage, D Robustly optimised plans in post-operative OPC and OCC patients are robust against inter-fraction setup variations and range uncertainty. D MFO plans in post-operative OPC and OCC patients are robust to inter-fraction uncertainties in setup and range when evaluated over multiple CT scans without compromising OAR mean dose. This is the first paper to evaluate inter-fraction MFO plan robustness in post-operative head and neck treatment.
Identifiants
pubmed: 31845816
doi: 10.1259/bjr.20190638
pmc: PMC7066971
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20190638Subventions
Organisme : Medical Research Council
ID : MC_U137686858
Pays : United Kingdom
Références
Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):738-749
pubmed: 29280468
Med Phys. 2013 May;40(5):051711
pubmed: 23635259
Phys Med Biol. 2015 Apr 7;60(7):2671-84
pubmed: 25768095
Radiother Oncol. 2019 Feb;131:127-134
pubmed: 30773179
Med Phys. 2011 Mar;38(3):1672-84
pubmed: 21520880
Radiother Oncol. 2016 May;119(2):221-8
pubmed: 27178143
Nutr Cancer. 2013;65(1):76-83
pubmed: 23368916
Radiother Oncol. 2020 Jan;142:124-132
pubmed: 31564553
Phys Med Biol. 2008 Feb 21;53(4):1043-56
pubmed: 18263957
Med Phys. 2015 Aug;42(8):4840-7
pubmed: 26233211
Br J Radiol. 2013 Jan;86(1021):20120288
pubmed: 23255545
Med Phys. 2012 Feb;39(2):1079-91
pubmed: 22320818
Phys Med Biol. 1996 Jan;41(1):111-24
pubmed: 8685250
Phys Med Biol. 2007 Feb 7;52(3):635-44
pubmed: 17228110
Phys Med Biol. 2007 May 21;52(10):2755-73
pubmed: 17473350